nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—UGT1A1—Mycophenolic acid—psoriasis	0.0653	0.0964	CbGbCtD
Erlotinib—CYP1A1—Clobetasol propionate—psoriasis	0.0614	0.0906	CbGbCtD
Erlotinib—UGT1A1—Mycophenolate mofetil—psoriasis	0.0365	0.0539	CbGbCtD
Erlotinib—CYP1A1—Methoxsalen—psoriasis	0.0322	0.0476	CbGbCtD
Erlotinib—ALB—Acitretin—psoriasis	0.0295	0.0436	CbGbCtD
Erlotinib—CYP2C8—Tazarotene—psoriasis	0.0289	0.0426	CbGbCtD
Erlotinib—CYP3A5—Beclomethasone—psoriasis	0.0279	0.0412	CbGbCtD
Erlotinib—CYP1A2—Clobetasol propionate—psoriasis	0.0274	0.0405	CbGbCtD
Erlotinib—CYP1A1—Cholecalciferol—psoriasis	0.0213	0.0315	CbGbCtD
Erlotinib—CYP1B1—Dexamethasone—psoriasis	0.0211	0.0311	CbGbCtD
Erlotinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0201	0.0296	CbGbCtD
Erlotinib—ABCG2—Hydrocortisone—psoriasis	0.0161	0.0238	CbGbCtD
Erlotinib—ABCG2—Cyclosporine—psoriasis	0.0152	0.0225	CbGbCtD
Erlotinib—CYP1A2—Methoxsalen—psoriasis	0.0144	0.0213	CbGbCtD
Erlotinib—ALB—Mycophenolate mofetil—psoriasis	0.0138	0.0204	CbGbCtD
Erlotinib—CYP2D6—Hydroxyurea—psoriasis	0.013	0.0192	CbGbCtD
Erlotinib—CYP2C8—Cholecalciferol—psoriasis	0.0123	0.0182	CbGbCtD
Erlotinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.0111	0.0164	CbGbCtD
Erlotinib—ALB—Prednisone—psoriasis	0.0111	0.0163	CbGbCtD
Erlotinib—CYP2C8—Mycophenolate mofetil—psoriasis	0.0107	0.0158	CbGbCtD
Erlotinib—ABCG2—Dexamethasone—psoriasis	0.01	0.0148	CbGbCtD
Erlotinib—CYP3A4—Calcitriol—psoriasis	0.0097	0.0143	CbGbCtD
Erlotinib—CYP1A1—Dexamethasone—psoriasis	0.00924	0.0136	CbGbCtD
Erlotinib—CYP3A5—Hydrocortisone—psoriasis	0.00892	0.0132	CbGbCtD
Erlotinib—CYP2C8—Hydrocortisone—psoriasis	0.00857	0.0127	CbGbCtD
Erlotinib—CYP3A5—Cyclosporine—psoriasis	0.00842	0.0124	CbGbCtD
Erlotinib—CYP2C8—Cyclosporine—psoriasis	0.0081	0.012	CbGbCtD
Erlotinib—ABCG2—Methotrexate—psoriasis	0.00804	0.0119	CbGbCtD
Erlotinib—CYP2D6—Cholecalciferol—psoriasis	0.00786	0.0116	CbGbCtD
Erlotinib—CYP3A4—Methoxsalen—psoriasis	0.00754	0.0111	CbGbCtD
Erlotinib—ABCB1—Mycophenolate mofetil—psoriasis	0.00723	0.0107	CbGbCtD
Erlotinib—ABCB1—Betamethasone—psoriasis	0.0062	0.00917	CbGbCtD
Erlotinib—ABCB1—Prednisolone—psoriasis	0.00612	0.00904	CbGbCtD
Erlotinib—ABCB1—Hydrocortisone—psoriasis	0.0058	0.00857	CbGbCtD
Erlotinib—ABCB1—Prednisone—psoriasis	0.00578	0.00854	CbGbCtD
Erlotinib—CYP3A5—Dexamethasone—psoriasis	0.00554	0.00819	CbGbCtD
Erlotinib—ALB—Methotrexate—psoriasis	0.00554	0.00819	CbGbCtD
Erlotinib—ABCB1—Cyclosporine—psoriasis	0.00548	0.0081	CbGbCtD
Erlotinib—CYP2C8—Dexamethasone—psoriasis	0.00533	0.00788	CbGbCtD
Erlotinib—CYP2D6—Cyclosporine—psoriasis	0.00516	0.00763	CbGbCtD
Erlotinib—CYP3A4—Cholecalciferol—psoriasis	0.005	0.00738	CbGbCtD
Erlotinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00433	0.0064	CbGbCtD
Erlotinib—CYP3A4—Triamcinolone—psoriasis	0.00433	0.0064	CbGbCtD
Erlotinib—CYP3A4—Betamethasone—psoriasis	0.00372	0.00549	CbGbCtD
Erlotinib—CYP3A4—Prednisolone—psoriasis	0.00367	0.00542	CbGbCtD
Erlotinib—ABCB1—Dexamethasone—psoriasis	0.00361	0.00533	CbGbCtD
Erlotinib—CYP3A4—Hydrocortisone—psoriasis	0.00348	0.00514	CbGbCtD
Erlotinib—CYP3A4—Prednisone—psoriasis	0.00346	0.00512	CbGbCtD
Erlotinib—CYP2D6—Dexamethasone—psoriasis	0.0034	0.00502	CbGbCtD
Erlotinib—CYP3A4—Cyclosporine—psoriasis	0.00328	0.00485	CbGbCtD
Erlotinib—ABCB1—Methotrexate—psoriasis	0.0029	0.00428	CbGbCtD
Erlotinib—CYP3A4—Dexamethasone—psoriasis	0.00216	0.00319	CbGbCtD
Erlotinib—Vandetanib—VEGFA—psoriasis	0.00182	1	CrCbGaD
Erlotinib—Shock—Prednisolone—psoriasis	8.91e-05	0.000374	CcSEcCtD
Erlotinib—Cough—Triamcinolone—psoriasis	8.9e-05	0.000374	CcSEcCtD
Erlotinib—Dyspnoea—Cyclosporine—psoriasis	8.87e-05	0.000372	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	8.84e-05	0.000371	CcSEcCtD
Erlotinib—Oedema—Hydrocortisone—psoriasis	8.84e-05	0.000371	CcSEcCtD
Erlotinib—Asthenia—Mycophenolic acid—psoriasis	8.82e-05	0.00037	CcSEcCtD
Erlotinib—Infection—Hydrocortisone—psoriasis	8.78e-05	0.000369	CcSEcCtD
Erlotinib—Insomnia—Mycophenolate mofetil—psoriasis	8.78e-05	0.000368	CcSEcCtD
Erlotinib—Dyspepsia—Cyclosporine—psoriasis	8.76e-05	0.000367	CcSEcCtD
Erlotinib—Nausea—Hydroxyurea—psoriasis	8.72e-05	0.000366	CcSEcCtD
Erlotinib—Pruritus—Mycophenolic acid—psoriasis	8.7e-05	0.000365	CcSEcCtD
Erlotinib—Shock—Hydrocortisone—psoriasis	8.7e-05	0.000365	CcSEcCtD
Erlotinib—Myalgia—Triamcinolone—psoriasis	8.68e-05	0.000364	CcSEcCtD
Erlotinib—Nervous system disorder—Hydrocortisone—psoriasis	8.67e-05	0.000364	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—psoriasis	8.67e-05	0.000364	CcSEcCtD
Erlotinib—Eye disorder—Prednisone—psoriasis	8.65e-05	0.000363	CcSEcCtD
Erlotinib—Dyspnoea—Mycophenolate mofetil—psoriasis	8.65e-05	0.000363	CcSEcCtD
Erlotinib—Decreased appetite—Cyclosporine—psoriasis	8.65e-05	0.000363	CcSEcCtD
Erlotinib—Infestation—Methotrexate—psoriasis	8.62e-05	0.000362	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—psoriasis	8.62e-05	0.000362	CcSEcCtD
Erlotinib—Depression—Methotrexate—psoriasis	8.59e-05	0.000361	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Cyclosporine—psoriasis	8.59e-05	0.00036	CcSEcCtD
Erlotinib—Skin disorder—Hydrocortisone—psoriasis	8.59e-05	0.00036	CcSEcCtD
Erlotinib—Fatigue—Cyclosporine—psoriasis	8.58e-05	0.00036	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—psoriasis	8.55e-05	0.000359	CcSEcCtD
Erlotinib—Dyspepsia—Mycophenolate mofetil—psoriasis	8.54e-05	0.000358	CcSEcCtD
Erlotinib—Constipation—Cyclosporine—psoriasis	8.51e-05	0.000357	CcSEcCtD
Erlotinib—Pain—Cyclosporine—psoriasis	8.51e-05	0.000357	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—psoriasis	8.47e-05	0.000356	CcSEcCtD
Erlotinib—Decreased appetite—Mycophenolate mofetil—psoriasis	8.44e-05	0.000354	CcSEcCtD
Erlotinib—Anorexia—Hydrocortisone—psoriasis	8.43e-05	0.000354	CcSEcCtD
Erlotinib—Diarrhoea—Mycophenolic acid—psoriasis	8.41e-05	0.000353	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—psoriasis	8.4e-05	0.000353	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—psoriasis	8.38e-05	0.000352	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.38e-05	0.000352	CcSEcCtD
Erlotinib—Oedema—Triamcinolone—psoriasis	8.32e-05	0.000349	CcSEcCtD
Erlotinib—Syncope—Dexamethasone—psoriasis	8.3e-05	0.000348	CcSEcCtD
Erlotinib—Syncope—Betamethasone—psoriasis	8.3e-05	0.000348	CcSEcCtD
Erlotinib—Pain—Mycophenolate mofetil—psoriasis	8.3e-05	0.000348	CcSEcCtD
Erlotinib—Constipation—Mycophenolate mofetil—psoriasis	8.3e-05	0.000348	CcSEcCtD
Erlotinib—Arrhythmia—Prednisone—psoriasis	8.27e-05	0.000347	CcSEcCtD
Erlotinib—Infection—Triamcinolone—psoriasis	8.27e-05	0.000347	CcSEcCtD
Erlotinib—Shock—Triamcinolone—psoriasis	8.19e-05	0.000344	CcSEcCtD
Erlotinib—Insomnia—Prednisolone—psoriasis	8.19e-05	0.000344	CcSEcCtD
Erlotinib—Alopecia—Prednisone—psoriasis	8.18e-05	0.000343	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—psoriasis	8.15e-05	0.000342	CcSEcCtD
Erlotinib—Gastrointestinal pain—Cyclosporine—psoriasis	8.13e-05	0.000341	CcSEcCtD
Erlotinib—Loss of consciousness—Betamethasone—psoriasis	8.13e-05	0.000341	CcSEcCtD
Erlotinib—Loss of consciousness—Dexamethasone—psoriasis	8.13e-05	0.000341	CcSEcCtD
Erlotinib—Dizziness—Mycophenolic acid—psoriasis	8.13e-05	0.000341	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—psoriasis	8.13e-05	0.000341	CcSEcCtD
Erlotinib—Mental disorder—Prednisone—psoriasis	8.11e-05	0.00034	CcSEcCtD
Erlotinib—Erythema—Prednisone—psoriasis	8.06e-05	0.000338	CcSEcCtD
Erlotinib—Malnutrition—Prednisone—psoriasis	8.06e-05	0.000338	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	8.05e-05	0.000338	CcSEcCtD
Erlotinib—Insomnia—Hydrocortisone—psoriasis	8e-05	0.000336	CcSEcCtD
Erlotinib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.93e-05	0.000333	CcSEcCtD
Erlotinib—Myalgia—Dexamethasone—psoriasis	7.88e-05	0.000331	CcSEcCtD
Erlotinib—Myalgia—Betamethasone—psoriasis	7.88e-05	0.000331	CcSEcCtD
Erlotinib—Body temperature increased—Cyclosporine—psoriasis	7.86e-05	0.00033	CcSEcCtD
Erlotinib—Abdominal pain—Cyclosporine—psoriasis	7.86e-05	0.00033	CcSEcCtD
Erlotinib—Anxiety—Dexamethasone—psoriasis	7.85e-05	0.00033	CcSEcCtD
Erlotinib—Anxiety—Betamethasone—psoriasis	7.85e-05	0.00033	CcSEcCtD
Erlotinib—Vomiting—Mycophenolic acid—psoriasis	7.82e-05	0.000328	CcSEcCtD
Erlotinib—Dyspepsia—Hydrocortisone—psoriasis	7.78e-05	0.000327	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—psoriasis	7.78e-05	0.000326	CcSEcCtD
Erlotinib—Rash—Mycophenolic acid—psoriasis	7.75e-05	0.000325	CcSEcCtD
Erlotinib—Dermatitis—Mycophenolic acid—psoriasis	7.75e-05	0.000325	CcSEcCtD
Erlotinib—Pain—Prednisolone—psoriasis	7.74e-05	0.000325	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—psoriasis	7.74e-05	0.000325	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—psoriasis	7.74e-05	0.000325	CcSEcCtD
Erlotinib—Headache—Mycophenolic acid—psoriasis	7.7e-05	0.000323	CcSEcCtD
Erlotinib—Decreased appetite—Hydrocortisone—psoriasis	7.68e-05	0.000323	CcSEcCtD
Erlotinib—Body temperature increased—Mycophenolate mofetil—psoriasis	7.67e-05	0.000322	CcSEcCtD
Erlotinib—Abdominal pain—Mycophenolate mofetil—psoriasis	7.67e-05	0.000322	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—psoriasis	7.64e-05	0.000321	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.63e-05	0.00032	CcSEcCtD
Erlotinib—Fatigue—Hydrocortisone—psoriasis	7.62e-05	0.00032	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—psoriasis	7.58e-05	0.000318	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.58e-05	0.000318	CcSEcCtD
Erlotinib—Pain—Hydrocortisone—psoriasis	7.56e-05	0.000317	CcSEcCtD
Erlotinib—Oedema—Betamethasone—psoriasis	7.55e-05	0.000317	CcSEcCtD
Erlotinib—Oedema—Dexamethasone—psoriasis	7.55e-05	0.000317	CcSEcCtD
Erlotinib—Insomnia—Triamcinolone—psoriasis	7.53e-05	0.000316	CcSEcCtD
Erlotinib—Infection—Betamethasone—psoriasis	7.5e-05	0.000315	CcSEcCtD
Erlotinib—Infection—Dexamethasone—psoriasis	7.5e-05	0.000315	CcSEcCtD
Erlotinib—Shock—Dexamethasone—psoriasis	7.43e-05	0.000312	CcSEcCtD
Erlotinib—Shock—Betamethasone—psoriasis	7.43e-05	0.000312	CcSEcCtD
Erlotinib—Dyspnoea—Triamcinolone—psoriasis	7.42e-05	0.000311	CcSEcCtD
Erlotinib—Nervous system disorder—Betamethasone—psoriasis	7.41e-05	0.000311	CcSEcCtD
Erlotinib—Nervous system disorder—Dexamethasone—psoriasis	7.41e-05	0.000311	CcSEcCtD
Erlotinib—Thrombocytopenia—Betamethasone—psoriasis	7.4e-05	0.00031	CcSEcCtD
Erlotinib—Thrombocytopenia—Dexamethasone—psoriasis	7.4e-05	0.00031	CcSEcCtD
Erlotinib—Dyspepsia—Triamcinolone—psoriasis	7.33e-05	0.000308	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—psoriasis	7.32e-05	0.000307	CcSEcCtD
Erlotinib—Nausea—Mycophenolic acid—psoriasis	7.3e-05	0.000307	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—psoriasis	7.23e-05	0.000303	CcSEcCtD
Erlotinib—Gastrointestinal pain—Hydrocortisone—psoriasis	7.23e-05	0.000303	CcSEcCtD
Erlotinib—Syncope—Prednisone—psoriasis	7.23e-05	0.000303	CcSEcCtD
Erlotinib—Anorexia—Betamethasone—psoriasis	7.2e-05	0.000302	CcSEcCtD
Erlotinib—Anorexia—Dexamethasone—psoriasis	7.2e-05	0.000302	CcSEcCtD
Erlotinib—Fatigue—Triamcinolone—psoriasis	7.18e-05	0.000301	CcSEcCtD
Erlotinib—Asthenia—Cyclosporine—psoriasis	7.14e-05	0.0003	CcSEcCtD
Erlotinib—Pain—Triamcinolone—psoriasis	7.12e-05	0.000299	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisone—psoriasis	7.08e-05	0.000297	CcSEcCtD
Erlotinib—Pruritus—Cyclosporine—psoriasis	7.04e-05	0.000295	CcSEcCtD
Erlotinib—Abdominal pain—Hydrocortisone—psoriasis	6.99e-05	0.000293	CcSEcCtD
Erlotinib—Body temperature increased—Hydrocortisone—psoriasis	6.99e-05	0.000293	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—psoriasis	6.97e-05	0.000293	CcSEcCtD
Erlotinib—Asthenia—Mycophenolate mofetil—psoriasis	6.96e-05	0.000292	CcSEcCtD
Erlotinib—Chills—Methotrexate—psoriasis	6.94e-05	0.000291	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.88e-05	0.000289	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Betamethasone—psoriasis	6.88e-05	0.000289	CcSEcCtD
Erlotinib—Pruritus—Mycophenolate mofetil—psoriasis	6.87e-05	0.000288	CcSEcCtD
Erlotinib—Myalgia—Prednisone—psoriasis	6.86e-05	0.000288	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—psoriasis	6.86e-05	0.000288	CcSEcCtD
Erlotinib—Anxiety—Prednisone—psoriasis	6.84e-05	0.000287	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—psoriasis	6.84e-05	0.000287	CcSEcCtD
Erlotinib—Insomnia—Dexamethasone—psoriasis	6.83e-05	0.000287	CcSEcCtD
Erlotinib—Insomnia—Betamethasone—psoriasis	6.83e-05	0.000287	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.81e-05	0.000286	CcSEcCtD
Erlotinib—Diarrhoea—Cyclosporine—psoriasis	6.81e-05	0.000286	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—psoriasis	6.78e-05	0.000284	CcSEcCtD
Erlotinib—Erythema—Methotrexate—psoriasis	6.74e-05	0.000283	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—psoriasis	6.74e-05	0.000283	CcSEcCtD
Erlotinib—Dyspepsia—Betamethasone—psoriasis	6.65e-05	0.000279	CcSEcCtD
Erlotinib—Dyspepsia—Dexamethasone—psoriasis	6.65e-05	0.000279	CcSEcCtD
Erlotinib—Diarrhoea—Mycophenolate mofetil—psoriasis	6.64e-05	0.000279	CcSEcCtD
Erlotinib—Body temperature increased—Triamcinolone—psoriasis	6.58e-05	0.000276	CcSEcCtD
Erlotinib—Dizziness—Cyclosporine—psoriasis	6.58e-05	0.000276	CcSEcCtD
Erlotinib—Oedema—Prednisone—psoriasis	6.58e-05	0.000276	CcSEcCtD
Erlotinib—Decreased appetite—Dexamethasone—psoriasis	6.57e-05	0.000276	CcSEcCtD
Erlotinib—Decreased appetite—Betamethasone—psoriasis	6.57e-05	0.000276	CcSEcCtD
Erlotinib—Infection—Prednisone—psoriasis	6.53e-05	0.000274	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Dexamethasone—psoriasis	6.52e-05	0.000274	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Betamethasone—psoriasis	6.52e-05	0.000274	CcSEcCtD
Erlotinib—Back pain—Methotrexate—psoriasis	6.52e-05	0.000273	CcSEcCtD
Erlotinib—Fatigue—Betamethasone—psoriasis	6.51e-05	0.000273	CcSEcCtD
Erlotinib—Fatigue—Dexamethasone—psoriasis	6.51e-05	0.000273	CcSEcCtD
Erlotinib—Shock—Prednisone—psoriasis	6.47e-05	0.000272	CcSEcCtD
Erlotinib—Pain—Betamethasone—psoriasis	6.46e-05	0.000271	CcSEcCtD
Erlotinib—Pain—Dexamethasone—psoriasis	6.46e-05	0.000271	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—psoriasis	6.45e-05	0.000271	CcSEcCtD
Erlotinib—Dizziness—Mycophenolate mofetil—psoriasis	6.42e-05	0.000269	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—psoriasis	6.39e-05	0.000268	CcSEcCtD
Erlotinib—Asthenia—Hydrocortisone—psoriasis	6.34e-05	0.000266	CcSEcCtD
Erlotinib—Vomiting—Cyclosporine—psoriasis	6.32e-05	0.000265	CcSEcCtD
Erlotinib—Rash—Cyclosporine—psoriasis	6.27e-05	0.000263	CcSEcCtD
Erlotinib—Anorexia—Prednisone—psoriasis	6.27e-05	0.000263	CcSEcCtD
Erlotinib—Dermatitis—Cyclosporine—psoriasis	6.27e-05	0.000263	CcSEcCtD
Erlotinib—Pruritus—Hydrocortisone—psoriasis	6.25e-05	0.000262	CcSEcCtD
Erlotinib—Headache—Cyclosporine—psoriasis	6.23e-05	0.000262	CcSEcCtD
Erlotinib—Gastrointestinal pain—Betamethasone—psoriasis	6.18e-05	0.000259	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dexamethasone—psoriasis	6.18e-05	0.000259	CcSEcCtD
Erlotinib—Vomiting—Mycophenolate mofetil—psoriasis	6.17e-05	0.000259	CcSEcCtD
Erlotinib—Rash—Mycophenolate mofetil—psoriasis	6.12e-05	0.000257	CcSEcCtD
Erlotinib—Dermatitis—Mycophenolate mofetil—psoriasis	6.11e-05	0.000257	CcSEcCtD
Erlotinib—Headache—Mycophenolate mofetil—psoriasis	6.08e-05	0.000255	CcSEcCtD
Erlotinib—Diarrhoea—Hydrocortisone—psoriasis	6.05e-05	0.000254	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—psoriasis	5.99e-05	0.000252	CcSEcCtD
Erlotinib—Dizziness—Prednisolone—psoriasis	5.99e-05	0.000251	CcSEcCtD
Erlotinib—Asthenia—Triamcinolone—psoriasis	5.97e-05	0.000251	CcSEcCtD
Erlotinib—Abdominal pain—Betamethasone—psoriasis	5.97e-05	0.000251	CcSEcCtD
Erlotinib—Abdominal pain—Dexamethasone—psoriasis	5.97e-05	0.000251	CcSEcCtD
Erlotinib—Body temperature increased—Dexamethasone—psoriasis	5.97e-05	0.000251	CcSEcCtD
Erlotinib—Body temperature increased—Betamethasone—psoriasis	5.97e-05	0.000251	CcSEcCtD
Erlotinib—Insomnia—Prednisone—psoriasis	5.95e-05	0.00025	CcSEcCtD
Erlotinib—Nausea—Cyclosporine—psoriasis	5.91e-05	0.000248	CcSEcCtD
Erlotinib—Pruritus—Triamcinolone—psoriasis	5.89e-05	0.000247	CcSEcCtD
Erlotinib—Cough—Methotrexate—psoriasis	5.88e-05	0.000247	CcSEcCtD
Erlotinib—Dizziness—Hydrocortisone—psoriasis	5.85e-05	0.000245	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—psoriasis	5.79e-05	0.000243	CcSEcCtD
Erlotinib—Nausea—Mycophenolate mofetil—psoriasis	5.76e-05	0.000242	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—psoriasis	5.73e-05	0.000241	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—psoriasis	5.73e-05	0.000241	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—psoriasis	5.73e-05	0.000241	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—psoriasis	5.72e-05	0.00024	CcSEcCtD
Erlotinib—Rash—Prednisolone—psoriasis	5.71e-05	0.00024	CcSEcCtD
Erlotinib—Dermatitis—Prednisolone—psoriasis	5.7e-05	0.000239	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.69e-05	0.000239	CcSEcCtD
Erlotinib—Fatigue—Prednisone—psoriasis	5.67e-05	0.000238	CcSEcCtD
Erlotinib—Headache—Prednisolone—psoriasis	5.67e-05	0.000238	CcSEcCtD
Erlotinib—Constipation—Prednisone—psoriasis	5.62e-05	0.000236	CcSEcCtD
Erlotinib—Vomiting—Hydrocortisone—psoriasis	5.62e-05	0.000236	CcSEcCtD
Erlotinib—Rash—Hydrocortisone—psoriasis	5.57e-05	0.000234	CcSEcCtD
Erlotinib—Dermatitis—Hydrocortisone—psoriasis	5.57e-05	0.000234	CcSEcCtD
Erlotinib—Headache—Hydrocortisone—psoriasis	5.54e-05	0.000232	CcSEcCtD
Erlotinib—Dizziness—Triamcinolone—psoriasis	5.5e-05	0.000231	CcSEcCtD
Erlotinib—Infection—Methotrexate—psoriasis	5.46e-05	0.000229	CcSEcCtD
Erlotinib—Asthenia—Betamethasone—psoriasis	5.42e-05	0.000227	CcSEcCtD
Erlotinib—Asthenia—Dexamethasone—psoriasis	5.42e-05	0.000227	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—psoriasis	5.39e-05	0.000226	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—psoriasis	5.38e-05	0.000226	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—psoriasis	5.38e-05	0.000226	CcSEcCtD
Erlotinib—Nausea—Prednisolone—psoriasis	5.38e-05	0.000226	CcSEcCtD
Erlotinib—Pruritus—Betamethasone—psoriasis	5.34e-05	0.000224	CcSEcCtD
Erlotinib—Pruritus—Dexamethasone—psoriasis	5.34e-05	0.000224	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—psoriasis	5.34e-05	0.000224	CcSEcCtD
Erlotinib—Vomiting—Triamcinolone—psoriasis	5.29e-05	0.000222	CcSEcCtD
Erlotinib—Nausea—Hydrocortisone—psoriasis	5.25e-05	0.00022	CcSEcCtD
Erlotinib—Rash—Triamcinolone—psoriasis	5.25e-05	0.00022	CcSEcCtD
Erlotinib—Dermatitis—Triamcinolone—psoriasis	5.24e-05	0.00022	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—psoriasis	5.24e-05	0.00022	CcSEcCtD
Erlotinib—Headache—Triamcinolone—psoriasis	5.21e-05	0.000219	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—psoriasis	5.2e-05	0.000218	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—psoriasis	5.2e-05	0.000218	CcSEcCtD
Erlotinib—Diarrhoea—Dexamethasone—psoriasis	5.17e-05	0.000217	CcSEcCtD
Erlotinib—Diarrhoea—Betamethasone—psoriasis	5.17e-05	0.000217	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—psoriasis	5.01e-05	0.00021	CcSEcCtD
Erlotinib—Dizziness—Betamethasone—psoriasis	4.99e-05	0.00021	CcSEcCtD
Erlotinib—Dizziness—Dexamethasone—psoriasis	4.99e-05	0.00021	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—psoriasis	4.97e-05	0.000209	CcSEcCtD
Erlotinib—Nausea—Triamcinolone—psoriasis	4.94e-05	0.000208	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—psoriasis	4.9e-05	0.000206	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—psoriasis	4.84e-05	0.000203	CcSEcCtD
Erlotinib—Vomiting—Dexamethasone—psoriasis	4.8e-05	0.000202	CcSEcCtD
Erlotinib—Vomiting—Betamethasone—psoriasis	4.8e-05	0.000202	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—psoriasis	4.78e-05	0.000201	CcSEcCtD
Erlotinib—Rash—Betamethasone—psoriasis	4.76e-05	0.0002	CcSEcCtD
Erlotinib—Rash—Dexamethasone—psoriasis	4.76e-05	0.0002	CcSEcCtD
Erlotinib—Dermatitis—Betamethasone—psoriasis	4.76e-05	0.0002	CcSEcCtD
Erlotinib—Dermatitis—Dexamethasone—psoriasis	4.76e-05	0.0002	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—psoriasis	4.75e-05	0.000199	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—psoriasis	4.74e-05	0.000199	CcSEcCtD
Erlotinib—Headache—Dexamethasone—psoriasis	4.73e-05	0.000199	CcSEcCtD
Erlotinib—Headache—Betamethasone—psoriasis	4.73e-05	0.000199	CcSEcCtD
Erlotinib—Asthenia—Prednisone—psoriasis	4.72e-05	0.000198	CcSEcCtD
Erlotinib—Pain—Methotrexate—psoriasis	4.7e-05	0.000197	CcSEcCtD
Erlotinib—Pruritus—Prednisone—psoriasis	4.65e-05	0.000195	CcSEcCtD
Erlotinib—Diarrhoea—Prednisone—psoriasis	4.5e-05	0.000189	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—psoriasis	4.5e-05	0.000189	CcSEcCtD
Erlotinib—Nausea—Betamethasone—psoriasis	4.49e-05	0.000188	CcSEcCtD
Erlotinib—Nausea—Dexamethasone—psoriasis	4.49e-05	0.000188	CcSEcCtD
Erlotinib—Dizziness—Prednisone—psoriasis	4.35e-05	0.000183	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—psoriasis	4.35e-05	0.000182	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—psoriasis	4.35e-05	0.000182	CcSEcCtD
Erlotinib—Vomiting—Prednisone—psoriasis	4.18e-05	0.000176	CcSEcCtD
Erlotinib—Rash—Prednisone—psoriasis	4.15e-05	0.000174	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—psoriasis	4.14e-05	0.000174	CcSEcCtD
Erlotinib—Headache—Prednisone—psoriasis	4.12e-05	0.000173	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—psoriasis	3.94e-05	0.000166	CcSEcCtD
Erlotinib—Nausea—Prednisone—psoriasis	3.91e-05	0.000164	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—psoriasis	3.89e-05	0.000163	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—psoriasis	3.76e-05	0.000158	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—psoriasis	3.64e-05	0.000153	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—psoriasis	3.5e-05	0.000147	CcSEcCtD
Erlotinib—Rash—Methotrexate—psoriasis	3.47e-05	0.000145	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—psoriasis	3.46e-05	0.000145	CcSEcCtD
Erlotinib—Headache—Methotrexate—psoriasis	3.44e-05	0.000145	CcSEcCtD
Erlotinib—Nausea—Methotrexate—psoriasis	3.27e-05	0.000137	CcSEcCtD
Erlotinib—EGFR—Innate Immune System—HLA-B—psoriasis	2.39e-05	0.000288	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.39e-05	0.000288	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—PPARG—psoriasis	2.39e-05	0.000288	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD8A—psoriasis	2.39e-05	0.000288	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—IL6—psoriasis	2.39e-05	0.000287	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—TNF—psoriasis	2.37e-05	0.000286	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NDUFA5—psoriasis	2.37e-05	0.000286	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—APOE—psoriasis	2.36e-05	0.000285	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—LEP—psoriasis	2.36e-05	0.000285	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.36e-05	0.000284	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-C—psoriasis	2.36e-05	0.000284	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—LEP—psoriasis	2.34e-05	0.000282	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD4—psoriasis	2.33e-05	0.000281	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TNFAIP3—psoriasis	2.33e-05	0.00028	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.32e-05	0.000279	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP2S1—psoriasis	2.31e-05	0.000279	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—TYK2—psoriasis	2.3e-05	0.000277	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP2S1—psoriasis	2.3e-05	0.000277	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HLA-B—psoriasis	2.3e-05	0.000277	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-E—psoriasis	2.29e-05	0.000276	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—IL6—psoriasis	2.28e-05	0.000275	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—psoriasis	2.27e-05	0.000273	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NFKBIA—psoriasis	2.26e-05	0.000272	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—IL6—psoriasis	2.25e-05	0.000271	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NDUFA5—psoriasis	2.23e-05	0.000269	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CXCL8—psoriasis	2.21e-05	0.000266	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.2e-05	0.000265	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NFKBIA—psoriasis	2.2e-05	0.000265	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—NFKB1—psoriasis	2.16e-05	0.00026	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.15e-05	0.000259	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CARM1—psoriasis	2.15e-05	0.000259	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—IL6—psoriasis	2.15e-05	0.000258	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—psoriasis	2.14e-05	0.000258	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—IL6—psoriasis	2.14e-05	0.000257	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HLA-A—psoriasis	2.13e-05	0.000257	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—IL6—psoriasis	2.12e-05	0.000256	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CRP—psoriasis	2.12e-05	0.000255	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—IL6—psoriasis	2.11e-05	0.000255	CbGpPWpGaD
Erlotinib—JAK3—Immune System—TYK2—psoriasis	2.1e-05	0.000253	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.1e-05	0.000253	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TYK2—psoriasis	2.09e-05	0.000252	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—VEGFA—psoriasis	2.08e-05	0.00025	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.04e-05	0.000246	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—PPARG—psoriasis	2.04e-05	0.000246	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2S1—psoriasis	2.02e-05	0.000243	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CXCL8—psoriasis	2.01e-05	0.000242	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IL6—psoriasis	2e-05	0.000241	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CARM1—psoriasis	2e-05	0.000241	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.99e-05	0.00024	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—IL6—psoriasis	1.99e-05	0.00024	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—IL6—psoriasis	1.99e-05	0.00024	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—IL6—psoriasis	1.97e-05	0.000237	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IFNG—psoriasis	1.97e-05	0.000237	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SOCS1—psoriasis	1.97e-05	0.000237	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-E—psoriasis	1.96e-05	0.000236	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—IL6—psoriasis	1.95e-05	0.000235	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriasis	1.95e-05	0.000234	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—IL6—psoriasis	1.95e-05	0.000234	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—STAT3—psoriasis	1.94e-05	0.000234	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NFKBIA—psoriasis	1.93e-05	0.000232	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL20—psoriasis	1.92e-05	0.000231	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SOCS1—psoriasis	1.91e-05	0.00023	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD4—psoriasis	1.9e-05	0.000229	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP2S1—psoriasis	1.9e-05	0.000229	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NDUFA5—psoriasis	1.89e-05	0.000228	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.87e-05	0.000225	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ICAM1—psoriasis	1.87e-05	0.000225	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NFKBIA—psoriasis	1.85e-05	0.000223	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—TYK2—psoriasis	1.85e-05	0.000223	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CARM1—psoriasis	1.82e-05	0.000219	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TYK2—psoriasis	1.8e-05	0.000217	CbGpPWpGaD
Erlotinib—MKNK1—Disease—STAT3—psoriasis	1.8e-05	0.000217	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TYK2—psoriasis	1.79e-05	0.000216	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—LEP—psoriasis	1.78e-05	0.000215	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—APOE—psoriasis	1.78e-05	0.000215	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—psoriasis	1.77e-05	0.000214	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.77e-05	0.000213	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.76e-05	0.000212	CbGpPWpGaD
Erlotinib—JAK3—Immune System—JUN—psoriasis	1.7e-05	0.000205	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.7e-05	0.000205	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD8A—psoriasis	1.7e-05	0.000204	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—psoriasis	1.67e-05	0.000201	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NFKBIA—psoriasis	1.66e-05	0.0002	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NFKB1—psoriasis	1.64e-05	0.000197	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SOCS1—psoriasis	1.63e-05	0.000197	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NFKB1—psoriasis	1.63e-05	0.000197	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-B—psoriasis	1.63e-05	0.000197	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2S1—psoriasis	1.61e-05	0.000194	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—TYK2—psoriasis	1.58e-05	0.00019	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CXCL8—psoriasis	1.57e-05	0.000189	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.56e-05	0.000188	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-A—psoriasis	1.51e-05	0.000182	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.51e-05	0.000181	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—JUN—psoriasis	1.5e-05	0.00018	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—psoriasis	1.48e-05	0.000178	CbGpPWpGaD
Erlotinib—JAK3—Immune System—STAT3—psoriasis	1.47e-05	0.000177	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—STAT3—psoriasis	1.47e-05	0.000177	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NDUFA5—psoriasis	1.46e-05	0.000176	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—JUN—psoriasis	1.46e-05	0.000176	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—APOE—psoriasis	1.45e-05	0.000175	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—LEP—psoriasis	1.45e-05	0.000175	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—psoriasis	1.45e-05	0.000175	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD8A—psoriasis	1.45e-05	0.000175	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CRP—psoriasis	1.44e-05	0.000174	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NFKB1—psoriasis	1.44e-05	0.000174	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—psoriasis	1.44e-05	0.000173	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—psoriasis	1.43e-05	0.000172	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NFKB1—psoriasis	1.41e-05	0.000169	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NFKB1—psoriasis	1.39e-05	0.000168	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-B—psoriasis	1.39e-05	0.000168	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.39e-05	0.000167	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-DRB1—psoriasis	1.38e-05	0.000166	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—psoriasis	1.37e-05	0.000165	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.37e-05	0.000165	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TYK2—psoriasis	1.36e-05	0.000164	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—psoriasis	1.36e-05	0.000163	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NFKBIA—psoriasis	1.35e-05	0.000163	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ICAM1—psoriasis	1.33e-05	0.00016	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.32e-05	0.000159	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CAT—psoriasis	1.32e-05	0.000159	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NFKBIA—psoriasis	1.32e-05	0.000158	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CARM1—psoriasis	1.31e-05	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-A—psoriasis	1.29e-05	0.000156	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—JUN—psoriasis	1.28e-05	0.000154	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—psoriasis	1.28e-05	0.000154	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—psoriasis	1.27e-05	0.000153	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—psoriasis	1.27e-05	0.000152	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—STAT3—psoriasis	1.26e-05	0.000152	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—psoriasis	1.26e-05	0.000152	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—STAT3—psoriasis	1.25e-05	0.000151	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2S1—psoriasis	1.24e-05	0.00015	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NOS2—psoriasis	1.23e-05	0.000149	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CARM1—psoriasis	1.23e-05	0.000149	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CRP—psoriasis	1.23e-05	0.000148	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CAT—psoriasis	1.23e-05	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NFKB1—psoriasis	1.23e-05	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—psoriasis	1.23e-05	0.000148	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.21e-05	0.000146	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.21e-05	0.000145	CbGpPWpGaD
Erlotinib—EGFR—Disease—HLA-A—psoriasis	1.19e-05	0.000144	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCL8—psoriasis	1.18e-05	0.000143	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NFKB1—psoriasis	1.18e-05	0.000142	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-DRB1—psoriasis	1.18e-05	0.000142	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.17e-05	0.000141	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.15e-05	0.000139	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ICAM1—psoriasis	1.13e-05	0.000136	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CARM1—psoriasis	1.13e-05	0.000136	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—psoriasis	1.13e-05	0.000136	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CARM1—psoriasis	1.12e-05	0.000135	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NFKBIA—psoriasis	1.12e-05	0.000135	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CAT—psoriasis	1.12e-05	0.000135	CbGpPWpGaD
Erlotinib—EGFR—Disease—APOE—psoriasis	1.11e-05	0.000134	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TYK2—psoriasis	1.11e-05	0.000134	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—JUN—psoriasis	1.1e-05	0.000133	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—psoriasis	1.1e-05	0.000132	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—psoriasis	1.08e-05	0.000131	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TYK2—psoriasis	1.08e-05	0.00013	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NFKB1—psoriasis	1.06e-05	0.000128	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.06e-05	0.000127	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SOCS1—psoriasis	1.06e-05	0.000127	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.05e-05	0.000127	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOS2—psoriasis	1.04e-05	0.000125	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.03e-05	0.000124	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—psoriasis	1.03e-05	0.000124	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—APOE—psoriasis	1.03e-05	0.000124	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—psoriasis	1.02e-05	0.000123	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IFNG—psoriasis	1.01e-05	0.000121	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TYK2—psoriasis	1.01e-05	0.000121	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CARM1—psoriasis	9.85e-06	0.000119	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—psoriasis	9.74e-06	0.000117	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL8—psoriasis	9.66e-06	0.000116	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—psoriasis	9.64e-06	0.000116	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—psoriasis	9.62e-06	0.000116	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—APOE—psoriasis	9.57e-06	0.000115	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—STAT3—psoriasis	9.53e-06	0.000115	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CARM1—psoriasis	9.28e-06	0.000112	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TYK2—psoriasis	9.2e-06	0.000111	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—psoriasis	9.05e-06	0.000109	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—JUN—psoriasis	8.98e-06	0.000108	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PPARG—psoriasis	8.94e-06	0.000108	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—psoriasis	8.82e-06	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL8—psoriasis	8.77e-06	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—psoriasis	8.75e-06	0.000105	CbGpPWpGaD
Erlotinib—ABL1—Immune System—JUN—psoriasis	8.72e-06	0.000105	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—APOE—psoriasis	8.71e-06	0.000105	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	8.64e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNG—psoriasis	8.62e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Disease—TYK2—psoriasis	8.5e-06	0.000102	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.44e-06	0.000102	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NFKB1—psoriasis	8.39e-06	0.000101	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARG—psoriasis	8.33e-06	0.0001	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—psoriasis	8.32e-06	0.0001	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAT—psoriasis	8.03e-06	9.67e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CARM1—psoriasis	7.86e-06	9.47e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	7.84e-06	9.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOE—psoriasis	7.8e-06	9.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—LEP—psoriasis	7.8e-06	9.39e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—psoriasis	7.77e-06	9.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—psoriasis	7.73e-06	9.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—psoriasis	7.69e-06	9.26e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAT—psoriasis	7.58e-06	9.13e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—psoriasis	7.58e-06	9.13e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—psoriasis	7.54e-06	9.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JUN—psoriasis	7.45e-06	8.97e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.35e-06	8.85e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—psoriasis	7.27e-06	8.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NFKBIA—psoriasis	7.27e-06	8.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NFKB1—psoriasis	7.17e-06	8.64e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—psoriasis	7.15e-06	8.61e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAT—psoriasis	6.95e-06	8.37e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAT—psoriasis	6.91e-06	8.33e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—psoriasis	6.65e-06	8.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—psoriasis	6.45e-06	7.76e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—psoriasis	6.24e-06	7.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CARM1—psoriasis	6.07e-06	7.31e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAT—psoriasis	6.06e-06	7.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TYK2—psoriasis	5.95e-06	7.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—psoriasis	5.95e-06	7.17e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—psoriasis	5.93e-06	7.14e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—psoriasis	5.89e-06	7.1e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAT—psoriasis	5.71e-06	6.88e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—psoriasis	5.43e-06	6.54e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—psoriasis	5.42e-06	6.53e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—psoriasis	5.4e-06	6.51e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—psoriasis	5.4e-06	6.51e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—psoriasis	5.37e-06	6.47e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—psoriasis	5.27e-06	6.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—psoriasis	5.18e-06	6.24e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—psoriasis	5.13e-06	6.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—psoriasis	4.93e-06	5.93e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAT—psoriasis	4.84e-06	5.82e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—psoriasis	4.82e-06	5.8e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—psoriasis	4.71e-06	5.67e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—psoriasis	4.71e-06	5.67e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—psoriasis	4.68e-06	5.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NFKB1—psoriasis	4.64e-06	5.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—psoriasis	4.5e-06	5.42e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—psoriasis	4.44e-06	5.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—psoriasis	4.21e-06	5.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—psoriasis	4.17e-06	5.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—psoriasis	4.16e-06	5.01e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—psoriasis	4.1e-06	4.94e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—psoriasis	3.86e-06	4.65e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—psoriasis	3.76e-06	4.53e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAT—psoriasis	3.73e-06	4.49e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—psoriasis	3.27e-06	3.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—psoriasis	3.18e-06	3.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—psoriasis	2.91e-06	3.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—psoriasis	2.9e-06	3.49e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—psoriasis	2.53e-06	3.04e-05	CbGpPWpGaD
